FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019445932> ?p ?o ?g. }

• W2019445932 endingPage "4207" @default.
• W2019445932 startingPage "4204" @default.
• W2019445932 abstract "New tools in drug development: The catalytic enantioselective fluorination and chlorination reactions of carbonyl compounds containing an additional binding site (see scheme) proceed with extremely high enantioselectivity and require low catalyst loadings (2–10 mol % dbfox-Ph/NiII). Asymmetric amplification is also observed in these enantioselective halogenations. The enantioselective electrophilic halogenation of carbonyl compounds represents one of the best established strategies for the construction of chiral CX bonds in organic chemistry.1 The resulting chiral halo compounds, especially fluorine-containing chiral organic molecules, are very fascinating in the field of medicinal chemistry.2 The unique hydrophobic, space-filling, and electronic properties of a fluorine atom can make substrates with CF bonds useful candidates for drug development. Next to fluorination, enantioselective chlorination is also an important topic with regard to some aspects of pharmaceuticals.3 Although recent rapid advances in the methodology of enantioselective halogenations have made great contributions in these fields,4–6 more efficient and more flexible methods are required. In this paper we describe highly enantioselective fluorination and chlorination reactions of carbonyl compounds that are capable of two-point binding. Both of the halogenations are catalyzed by the catalyst dbfox-Ph/NiII with very high enantioselectivity up to 99 % ee. Furthermore, we also present the first significant examples of asymmetric amplification in enantioselective halogenations starting with the catalyst at 45 % enantiopurity to afford the halogenated compounds with significantly increased ee values of >90 %. We initiated the study of asymmetric fluorination reaction of β-keto esters 1 a–g, since α-fluorinated β-keto esters such as telithromycin have attractive antibiotic activity.7 Recently, we found that chiral CuII and NiII complexes of phenylbis(oxazoline) (box-Ph) effectively catalyze the enantioselective fluorination of β-keto esters with N-fluorobenzenesulfonimide (NFSI); however, the enantioselectivity was not high enough.6d In previous works by one of us, the dbfox-Ph ligand1 was highly effective in asymmetric Diels–Alder and Michael addition reactions.8 Thus we turned to this ligand to improve the fluorination reaction. A solution of 1 a in CH2Cl2 was treated with 1.2 equiv of NFSI in the presence of a catalytic amount of dbfox-Ph/Ni(ClO4)2⋅6 H2O at room temperature to afford the α-fluoro compound 2 a in high yield with an extremely high enantioselectivity (Scheme 1; Table 1, entry 1, 99 % ee). The ester 1 a proved to be the ideal yardstick to measure our results, as it has been studied by many investigators under a variety of conditions for enantioselective fluorinations.4–6 Enantioselective halogenations of substrates capable of two-point binding using dbfox-Ph/NiII with NFSI or CF3SO2Cl. Entry Substrate 1 (X=H) Product 2 (X=F) t [h] Yield [%] ee [%] 1 0 a: R=tBu, n=1 3 76 99 (S) 2 b: R=Ad, n=1 2 71 99 3 c: R=L-Men, n=1 2 66 99 4 d: Ad, n=2 3 88 95 5 0 e: tBu, n=1 2 84 93 6 f: tBu, n=2 2 86 99 7[b] 0 g 18 75 83 8[c,d] 0 h: Me 35 73 93 9[c] i: Ph 5 72 96 10[c] 0 j 14 71 93 (S) 11[e] 0 a: R=tBu, n=1 6 93 99 (S) The scope of the fluorination of a series of β-keto esters 1 b–g was investigated; we found that the dbfox-Ph/NiII catalyst exhibits excellent enantioselectivity as well (Table 1, entries 2–7). In most cases, our fluorination was more enantioselective than the reported procedures owing to the remarkable control of the enantioface of enolates by the dbfox-Ph/NiII complex.9 It is notable that catalyst loading can be reduced to 2 mol % without loss of enantioselectivity (entries 1 and 11). To demonstrate the further synthetic utility of this dbfox-Ph/NiII fluorination system, we tested other substrates capable of two-point binding. Pharmaceutically important fluorooxindoles10 2 h–j were selected as target molecules. Although we reported the enantioselective synthesis of fluorooxindoles using a combination of cinchona alkaloids and Selectfluor,6c no catalytic enantioselective method has been described. Under similar reaction conditions, a significant degree of enantioselectivity has been obtained irrespective of the substrates used (Table 1, entries 8–10). It is noted that fluorooxindole 2 j was converted into MaxiPost,6c, 10 an effective opener of maxi-K channels, by cleavage of the Boc group. This is the first example of a catalytic enantioselective preparation of MaxiPost. Highly enantioselective chlorinations of ketones, acid halides, and aldehydes have been reported; however, asymmetric chlorination of β-keto esters has relatively low enantioselectivity.5 In addition, no enantioselective syntheses of α-chlorooxindoles, which are potentially important in medicinal chemistry, have been reported.11 We were pleased to find that our dbfox-Ph/NiII system was also effective for the asymmetric chlorination of a series of substrates including β-keto esters 1 a–d and oxindoles 1 i and 1 j (Table 2). The substrates were chlorinated smoothly with CF3SO2Cl under our optimized conditions to produce 3 a–d, 3 i, and 3 j with high enantioselectivity. Chlorooxindole 3 j can be converted to BMS225113, a pharmaceutically important chlorooxindole.11 It is highly noted that CF3SO2Cl as a chlorinating agent is essential to achieve high enantioselectivity, since N-chlorosuccimide (NCS) under the same conditions provided poorer results (entry 2 vs entry 3). Entry 1 R 3 t [h] Yield [%] ee [%] 1 1 a tBu 3 a 10 72 97 2 1 b Ad 3 b 17 85 97 3[b] 1 b Ad 3 b 3 85 54 4 1 c L-Men 3 c 9 66 94 5 1 d Ad 3 d 45 61(71)[d] 98 6[c] 1 i Ph 3 i 20 93 61 7[c] 1 j – 3 j 17 93 60 We finally examined experiments of chiral amplification12, 13 in the halogenations on our systems. Fluorinations of 1 a with NFSI were carried out in the presence of Ni(ClO4)2⋅6 H2O and dbfox-Ph, enantiopurities of which were varied from 11 % to 60 %. Figure 1 shows the relationship between the enantiomeric purity of the dbfox-Ph ligand used and the enantioselectivity observed for 2 a when the molar ratio of dbfox-Ph to Ni(ClO4)2⋅6 H2O was 1.1:1 and the catalyst loading was 10 mol %. When the dbfox-Ph ligand had ee values of 45 % and 11 %, 2 a was obtained with 99 % and 66 % ee, respectively. A similar positive nonlinear effect of chiral amplification was also observed in the chlorination of 1 b with CF3SO2Cl under the same conditions, and dbfox-Ph with >45 % enantiopurity was required to obtain the enantioenriched products 3 b with >90 % ee. Chiral amplification in the halogenations of 1 a,b with NFSI or CF3SO2Cl catalyzed by dbfox-Ph/Ni(ClO4)2⋅6 H2O. In conclusion, the catalytic enantioselective fluorination and chlorination reactions of carbonyl compounds structurally capable of two-point binding were achieved with extremely high enantioselectivity by the use of the dbfox-Ph14/NiII complex. In addition, this system led to not only the first catalytic enantioselective synthesis of MaxiPost and BMS225113, but also the first observation of asymmetric amplification in halogenation reactions of β-keto esters.13 We assumed octahedral complexes coordinated with a water molecule for 1 a/dbfox-Ph/NiII, 1 j/ dbfox -Ph/NiII optimized using MM2 in the light of the X-ray structure of the dbfox-Ph/NiII complex (Figure 2).8 In these complexes, one of the faces is covered so efficiently that the halogenating agents approach from the Si face of the substrates. The details are now under investigation. Optimized structures of the complexes of 1 a/dbfox-Ph/NiII and 1 j/dbfox-Ph/NiII. Supporting information for this article is available on the WWW under http://www.wiley-vch.de/contents/jc_2002/2005/z501041_s.pdf or from the author. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W2019445932 created "2016-06-24" @default.
• W2019445932 creator A5004068447 @default.
• W2019445932 creator A5009221132 @default.
• W2019445932 creator A5029173415 @default.
• W2019445932 creator A5032153600 @default.
• W2019445932 creator A5037788901 @default.
• W2019445932 creator A5077654635 @default.
• W2019445932 creator A5078520393 @default.
• W2019445932 date "2005-06-23" @default.
• W2019445932 modified "2023-10-12" @default.
• W2019445932 title "Highly Enantioselective Catalytic Fluorination and Chlorination Reactions of Carbonyl Compounds Capable of Two-Point Binding" @default.
• W2019445932 cites W180766444 @default.
• W2019445932 cites W1978201211 @default.
• W2019445932 cites W1981902823 @default.
• W2019445932 cites W1982446660 @default.
• W2019445932 cites W1984868632 @default.
• W2019445932 cites W1985451717 @default.
• W2019445932 cites W1996203458 @default.
• W2019445932 cites W2001471487 @default.
• W2019445932 cites W2012896074 @default.
• W2019445932 cites W2012915950 @default.
• W2019445932 cites W2014558089 @default.
• W2019445932 cites W2022315139 @default.
• W2019445932 cites W2022624267 @default.
• W2019445932 cites W2035498129 @default.
• W2019445932 cites W2035822436 @default.
• W2019445932 cites W2080830650 @default.
• W2019445932 cites W2086841165 @default.
• W2019445932 cites W2086885624 @default.
• W2019445932 cites W2088141349 @default.
• W2019445932 cites W2096077819 @default.
• W2019445932 cites W2102182663 @default.
• W2019445932 cites W2108880523 @default.
• W2019445932 cites W2142405803 @default.
• W2019445932 cites W2151656086 @default.
• W2019445932 cites W2153212528 @default.
• W2019445932 cites W2155664589 @default.
• W2019445932 cites W2165172030 @default.
• W2019445932 cites W2165411663 @default.
• W2019445932 cites W2166176365 @default.
• W2019445932 cites W2950738401 @default.
• W2019445932 cites W2951233585 @default.
• W2019445932 cites W2951263354 @default.
• W2019445932 cites W2951953897 @default.
• W2019445932 cites W2952731267 @default.
• W2019445932 cites W2953278874 @default.
• W2019445932 cites W4241569953 @default.
• W2019445932 cites W4255559941 @default.
• W2019445932 cites W4256601871 @default.
• W2019445932 cites W4361989844 @default.
• W2019445932 cites W61928364 @default.
• W2019445932 doi "https://doi.org/10.1002/anie.200501041" @default.
• W2019445932 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15942966" @default.
• W2019445932 hasPublicationYear "2005" @default.
• W2019445932 type Work @default.
• W2019445932 sameAs 2019445932 @default.
• W2019445932 citedByCount "304" @default.
• W2019445932 countsByYear W20194459322012 @default.
• W2019445932 countsByYear W20194459322013 @default.
• W2019445932 countsByYear W20194459322014 @default.
• W2019445932 countsByYear W20194459322015 @default.
• W2019445932 countsByYear W20194459322016 @default.
• W2019445932 countsByYear W20194459322017 @default.
• W2019445932 countsByYear W20194459322018 @default.
• W2019445932 countsByYear W20194459322019 @default.
• W2019445932 countsByYear W20194459322020 @default.
• W2019445932 countsByYear W20194459322021 @default.
• W2019445932 countsByYear W20194459322022 @default.
• W2019445932 countsByYear W20194459322023 @default.
• W2019445932 crossrefType "journal-article" @default.
• W2019445932 hasAuthorship W2019445932A5004068447 @default.
• W2019445932 hasAuthorship W2019445932A5009221132 @default.
• W2019445932 hasAuthorship W2019445932A5029173415 @default.
• W2019445932 hasAuthorship W2019445932A5032153600 @default.
• W2019445932 hasAuthorship W2019445932A5037788901 @default.
• W2019445932 hasAuthorship W2019445932A5077654635 @default.
• W2019445932 hasAuthorship W2019445932A5078520393 @default.
• W2019445932 hasBestOaLocation W20194459321 @default.
• W2019445932 hasConcept C146686406 @default.
• W2019445932 hasConcept C161790260 @default.
• W2019445932 hasConcept C178790620 @default.
• W2019445932 hasConcept C185592680 @default.
• W2019445932 hasConcept C21951064 @default.
• W2019445932 hasConcept C65973085 @default.
• W2019445932 hasConceptScore W2019445932C146686406 @default.
• W2019445932 hasConceptScore W2019445932C161790260 @default.
• W2019445932 hasConceptScore W2019445932C178790620 @default.
• W2019445932 hasConceptScore W2019445932C185592680 @default.
• W2019445932 hasConceptScore W2019445932C21951064 @default.
• W2019445932 hasConceptScore W2019445932C65973085 @default.
• W2019445932 hasIssue "27" @default.
• W2019445932 hasLocation W20194459321 @default.
• W2019445932 hasLocation W20194459322 @default.
• W2019445932 hasOpenAccess W2019445932 @default.
• W2019445932 hasPrimaryLocation W20194459321 @default.
• W2019445932 hasRelatedWork W1961260936 @default.
• W2019445932 hasRelatedWork W1982612425 @default.

• next